Prior information notice
This notice is for prior information only
Section I: Contracting
authority
I.1) Name and addresses
Betsi Cadwaladr University Health Board
Headquarters, Ysbyty Gwynedd, Penrhosgarnedd
Bangor
LL57 2PW
UK
Contact person: Victoria Allum
Telephone: +44 2921501263
E-mail: vicky.allum@wales.nhs.uk
NUTS: UK
Internet address(es)
Main address: https://bcuhb.nhs.wales/
Address of the buyer profile: https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA88547
I.2) Joint procurement
The contract is awarded by a central purchasing body
I.3) Communication
Additional information can be obtained from the abovementioned address
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Edoxaban Review Service
Reference number: BCU-MSP02-Edoxaban
II.1.2) Main CPV code
85121100
II.1.3) Type of contract
Services
II.1.4) Short description
The service is to review those prescribed edoxaban in primary care with a view to changing them to a more cost effective alternative.
II.1.5) Estimated total value
Value excluding VAT:
322 860.00
GBP
II.1.6) Information about lots
This contract is divided into lots:
No
II.2) Description
II.2.3) Place of performance
NUTS code:
UKL11
UKL12
UKL13
UKL23
II.2.4) Description of the procurement
Edoxaban Review Service is a service that requires a clinical review of all patients prescribed edoxaban for atrial fibrillation registered with GPs in BCUHB to assess if they are suitable for a more cost effective alternative and then change those that are.
Part 1 - Edoxaban Patient Review
Clinical review of the records of patients prescribed edoxaban.
Anyone not deemed suitable for the switch must be evidenced in the records, consider using the phrase
Edoxaban switch not clinically appropriate (no code) or,
Edoxaban contraindicated (SNOMED CT:2949391000000118) or,
Adverse reaction to edoxaban (SNOMED CT:1957181000006103).
Those deemed suitable for a switch proceed to a consultation with the patient or their representative. Consultations to switch edoxaban to generic apixaban or generic rivaroxaban can be done via telephone, virtually or face-to-face.
This must be documented in the notes, consider using the phrase
Edoxaban switch clinically appropriate (no code) or,
Edoxaban declined (SNOMED CT:1443911000000106)
Part 2 - Edoxaban Patient Review that results in a switch to generic apixaban or generic rivaroxaban
If clinically appropriate and the patient agrees to the switch to either generic rivaroxaban or generic apixaban; prescribe as indicated.
II.3) Estimated date of publication of contract notice:
09/07/2026
Section IV: Procedure
IV.1) Description
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
Section VI: Complementary information
VI.3) Additional information
This is a Provider Selection Regime Wales (PSR Wales) intended approach notice. The awarding of this contract is subject to the Health Services (Provider Selection Regime) (Wales) Regulations 2025. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015/Procurement Act 2023 do not apply to this award.
The decision makers will be the Heads of Pharmacy for primary care and community services and Medical Directors (East, Central and West) ratified by the Contract Management Group.
The intention is to award a contract using the most suitable provider process.
Publication of notice on 9th July, 14 days to respond by 22nd July. any queries and all responses to be sent to vicky.allum@wales.nhs.uk. Any responses received after this date will not be considered.
NOTE: To register your interest in this notice and obtain any additional information please visit the Sell2Wales Web Site at http://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=166883.
(WA Ref:166883)
VI.5) Date of dispatch of this notice
09/07/2026